Flow cytometry platform from LeukoDx secures investment commitments of up to $8M
Flow cytometry platform developer LeukoDx (Jerusalem, Israel) has entered into agreements for investments totaling up to $8 million over the next three years, which should enable the company to take developing its Point of Care flow cytometry platform to the registration stage.
The initial $1.6 million tranche of funding was closed with a US-based private equity group and support from a European life science investor, as well as from historical investors. The remainder of the investment is subject to validation of agreed-upon milestones, which are planned to be reached over the next two years.
In securing the financing, the company can now focus its efforts on rolling out the platform's final development stages and perform its initial tests, states Julien Meissonnier, LeukoDx president and CEO. With the platform, the company aims to deliver flow cytometry in-vitro diagnostics (IVD) test results in 10 minutes from a single drop of blood on an automated disposable cartridge, he says.
Among the potential assays to be included to measure white blood cell activity is CD64 neutrophil activation, which is being developed under exclusive license from Trillium Diagnostics for detecting and monitoring infections and sepsis. The device will allow for rapid clinical decision-making in patient settings such as neonatal and intensive care units, emergency departments, and in remote locations lacking access to diagnostic medical laboratories. The company is seeking collaboration and partnership with biotechnology and IVD companies to broaden the range of test candidates to be implemented on its platform.
-----
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!